Morgan Stanley Atara Biotherapeutics, Inc. Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATRA
# of Institutions
7Shares Held
2.89MCall Options Held
0Put Options Held
0-
Kpcb Xv Associates, LLC1.88MShares$21.4 Million19.79% of portfolio
-
Antipodean Advisors LLC New York, NY1MShares$11.4 Million8.12% of portfolio
-
Ifp Advisors, Inc4.5KShares$51,3000.0% of portfolio
-
American Portfolios Advisors Holbrook, NY4.5KShares$51,3000.0% of portfolio
-
Wipfli Financial Advisors Llc,3.08KShares$35,1000.0% of portfolio
About Atara Biotherapeutics, Inc.
- Ticker ATRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,362,304
- Market Cap $1.08B
- Description
- Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...